var data={"title":"Society guideline links: Benzodiazepine use disorder and withdrawal","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Society guideline links: Benzodiazepine use disorder and withdrawal</div><p class=\"disclosureLink\"></p><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p><strong>Introduction</strong> &mdash; This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.</p><p>The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.</p><p>Links to related guidelines are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-opioid-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opioid use disorder and withdrawal&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-alcohol-use-disorders-and-withdrawal\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Alcohol use disorders and withdrawal&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-cannabis-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Cannabis use disorder and withdrawal&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-stimulant-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Stimulant use disorder and withdrawal&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4192622885\"><span class=\"h1\">International</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.wpro.who.int/publications/docs/ClinicalGuidelines_forweb.pdf&amp;token=wWKRLdp5c8TglhddSNxU0eTTsW5O8h8DBWCfiqTuQBgdJwiLa+cLDY1u5i5H47cc8HzG/cb7kCngKGNRJbTx5Od/xabAlrYo4Y15nZ+ANhc=&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">World Health Organization (WHO): Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings</a> (2009)</p><p/><p class=\"headingAnchor\" id=\"H3572600654\"><span class=\"h1\">Canada</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.aacp.com/article/buy_now/?id=173&amp;token=IQxLzDq4doJGUgaZgeIY061EXt/WfBFEN0a7NflqbMRJAOSVBubSwpwy2F1lTFHZg+pJzkKUqW12tfaeozOKMQ==&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">The Canadian Network for Mood and Anxiety Treatments (CANMAT): Recommendations for the management of patients with mood disorders and comorbid substance use disorders</a> (2012)</p><p/><p class=\"headingAnchor\" id=\"H96064164\"><span class=\"h1\">United States</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.aatod.org/guidelines-for-addressing-benzodiazepine-use-in-opioid-treatment-programs-otps/&amp;token=nWSc2+cKAhZPgUE0wI4updRmbNbL8lIK+N5k7sbiZ0z5hEy4RWfTjsgVzfYvhYzdmnKqlHRy2KrEG7+LKz6H1/gLHNWsvlevJB99x1oikQeyIKTtlQQE4uqFGXQ3mm4d&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">American Association for the Treatment of Opioid Dependence, Inc (AATOD): Guidelines for addressing benzodiazepine use in opioid treatment programs (OTPs)</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://annals.org/aim/article/2613555/health-public-policy-facilitate-effective-prevention-treatment-substance-use-disorders&amp;token=a4O62W+TYTdmIEIEbiDFLDV+Z4ItkGxsxLt5XZs9g0v6jL21tYAMTCr5eNAoGHy2W6c/aP1i2RazCnP7EK8YPWs4XM6YhW8vY4DtM8QJbZm31BSNwRn6dYlvlLEhxSx6TAWuu+yRWEGLrSKqmSJcRg==&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">American College of Physicians (ACEP): Position paper on health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf&amp;token=sL+p+gWoM5K8OZ3TcR7z2WAY32Ka/u1lbC6jdvtVYplDI0rs/DHw81TdGI6zVlnNCLP+1pMC10A52nend3MprFknSAx+rhIRQPiX12p6yhTzdn4R1+LqwKt+My4GrnOr&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">US Department of Veterans Affairs/Department of Defense (VA/DoD): Clinical practice guideline for the management of substance use disorders</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse-watch.pdf&amp;token=Gqp4B20mCnqM0Au3I5S6e4ySd78beD0XF5YnI+oJS15wdZS/y/hD3WjJGzAD8WnA7cNKrN5B1dLzX0JVmsocVtUJlunzcBoOI1rhfTlGiTJcL5a/e2isiuMux179Li6F&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">American Psychiatric Association (APA): Guideline watch &minus; Practice guideline for the treatment of patients with substance abuse disorders, 2nd edition</a> (2007)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf&amp;token=FbcQzE9bBRIlfE+LIVNMKlgcvu6vo+MBYOxDi3oL5UDh3e+3z7lNsRyOWCjaGoqgznxBcI8uyc0QW6k9DqaQWu6Awo4SbNqb06JsvwVY/EyIE8arj9GtsmW2ILUDjxam&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">APA: Practice guideline for the treatment of patients with substance use disorders, 2nd edition</a> (2006)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK64115/pdf/Bookshelf_NBK64115.pdf&amp;token=wEsKVFvqlKzpT+qOtddW/y3+Lj0shalBW+L1ZyL4trzQNKrXNRfnbDB+moin6vffKWIqcE32vsILtI122PbBvZMEBHF7eogxToXG722IQ+8=&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">Substance Abuse and Mental Health Services Administration (SAMHSA): Detoxification and substance abuse treatment &minus; A Treatment Improvement Protocol (TIP)</a> (2006)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK64197/pdf/Bookshelf_NBK64197.pdf&amp;token=wEsKVFvqlKzpT+qOtddW/y3+Lj0shalBW+L1ZyL4trxbDALImH1NH6oNWBeAdDZEKWIqcE32vsILtI122PbBvXo2keP3V4XfqfEwDbHnWJE=&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">SAMHSA: Substance abuse treatment for persons with co-occurring disorders &minus; A Treatment Improvement Protocol (TIP)</a> (2005) </p><p/><p class=\"headingAnchor\" id=\"H3206658788\"><span class=\"h1\">United Kingdom</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ng64/resources/drug-misuse-prevention-targeted-interventions-pdf-1837573761733&amp;token=kMe9uRQl8n6Yqa7SsPcKXWugr9OZKWl0+Zy9LGGwH37BPMTNG8LXlIdTZyqu+iN8OX2CphJBbsKoWmUjucsq/5vnWVzcq3Jrv35AdAGP0iLDu20omtJPkbov9dKupG+46ZRkZEZZxHsx1XABuOq6ng==&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">National Institute for Health and Care Excellence (NICE): Guideline for drug misuse prevention &minus; Targeted interventions</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ng46/resources/controlled-drugs-safe-use-and-management-pdf-1837456188613&amp;token=+mpNJocdpZnrt+jGUOCISiDGNXCV96tXvU0prNynxE/q14rkztOiaqq/FhFcVQCpol3EPwBITtKfCfVpj34nEr2C5mF4qR7AkQQjUIx0j0MMZllXoSDjE5X67pNr4RMkrwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">NICE: Guideline on controlled drugs &minus; Safe use and management</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/qs23/resources/drug-use-disorders-in-adults-pdf-2098544097733&amp;token=uDPjmwDb8i/Vlgj5lAYoO0KVHv49ff74CDWiLASaVcIc3V+XFJNJc/d6BSHK09LQNNkkNsChy6F/U6PkBkOF6TeLqnGmf95ZDiRymWz55G/SmJCsKN4+MG0pKWOeQmWh&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">NICE: Quality standard on drug use disorders in adults</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/cg120/resources/coexisting-severe-mental-illness-psychosis-and-substance-misuse-assessment-and-management-in-healthcare-settings-pdf-35109443184325&amp;token=aHS0ygdHuR325ZXEG9ZQZwxyXlsO7kg7mGKzikrJzS/O3zn6z7HC2glXzXnw3x0eqKVkqXV1efX8ww/TZrSaiFfdBIjQRootpee5J8TgdF0s1FblxHmj6thDu1CsWypxLIkaUpk7tnadnNp45nzsijbn5uk206WZ5lA6btdkE4UI1gAdVQV3EhwQzO4v6epo&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">NICE: Clinical guideline on coexisting severe mental illness (psychosis) and substance misuse &minus; Assessment and management in healthcare settings</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nice.org.uk/guidance/cg51/resources/drug-misuse-in-over-16s-psychosocial-interventions-pdf-975502451653&amp;token=8xbYM37JZ8sy+tPQo4gcyfDVwJi/BxmWOiNU1U0d5AMfA7tE4WBwnLb5yhYnSoNeaSo4IRIc7vKn8JRy3OvXDJsTyNrW2cr+mUdqgx1VaIYQ1HuMlqwpAQeVMWiD4077cY3veHFXwbO1+24Uupx4mQ==&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">NICE: Clinical guideline on drug misuse in over 16s &minus; Psychosocial interventions</a> (2007)</p><p/><p class=\"headingAnchor\" id=\"H1692732144\"><span class=\"h1\">Australia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.clinicalguidelines.gov.au/portal/2492/alcohol-and-other-drug-withdrawal-practice-guidelines&amp;token=GxPhp9fsxndc/7KtdKu0a1/6oBrR1bGgVbW3kXDFWuvs5oO6bnM9xSVpiO50Lqe3jtlaqs6O/hQYopTqlEOCqdkPCwQbEAU/wxxAmMKxhI08IHekChaijqiap12LMflt&amp;TOPIC_ID=114814\" target=\"_blank\" class=\"external\">Australian National Health and Medical Research Council (NHMRC): Alcohol and other drug withdrawal &ndash; Practice guidelines, 2nd edition</a> (2012)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 114814 Version 1.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H4192622885\" id=\"outline-link-H4192622885\">International</a></li><li><a href=\"#H3572600654\" id=\"outline-link-H3572600654\">Canada</a></li><li><a href=\"#H96064164\" id=\"outline-link-H96064164\">United States</a></li><li><a href=\"#H3206658788\" id=\"outline-link-H3206658788\">United Kingdom</a></li><li><a href=\"#H1692732144\" id=\"outline-link-H1692732144\">Australia</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-alcohol-use-disorders-and-withdrawal\" class=\"medical medical_society_guidelines\">Society guideline links: Alcohol use disorders and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-cannabis-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">Society guideline links: Cannabis use disorder and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opioid-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">Society guideline links: Opioid use disorder and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-stimulant-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">Society guideline links: Stimulant use disorder and withdrawal</a></li></ul></div></div>","javascript":null}